Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Liabilities and Shareholders Equity (2016 - 2025)

PAVmed has reported Liabilities and Shareholders Equity over the past 6 years, most recently at $38.8 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 26.59% year-over-year to $38.8 million; the TTM value through Dec 2025 reached $173.6 million, up 31.14%, while the annual FY2025 figure was $38.8 million, 26.59% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $38.8 million at PAVmed, up from $38.1 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $87.0 million in Q4 2021 and troughed at $25.0 million in Q3 2024.
  • A 5-year average of $51.1 million and a median of $45.6 million in 2021 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 339.76% in 2021 and later plummeted 42.94% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $87.0 million in 2021, then tumbled by 37.94% to $54.0 million in 2022, then tumbled by 38.65% to $33.1 million in 2023, then fell by 7.42% to $30.7 million in 2024, then rose by 26.59% to $38.8 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for PAVM at $38.8 million in Q4 2025, $38.1 million in Q3 2025, and $43.9 million in Q2 2025.